Skip to main content

Table 4 SVR12 of LDV/SOF by regimen and different treatment duration

From: Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis

Response

SVR12 (N = 711)

Heterogeneity

Pb value

Studies

Total, n/N

Rate (95% CI)

I2 (%)

Pa

Overall

644/711

89.8 (85.9–92.7)

47.6

0.0336

 

12

By regimes

 LDV/SOF

436/484

89.2 (83.4–93.1)

55.6

0.7452

0.0274

9

 LDV/SOF ± RBV

193/211

90.4 (83.6–94.5)

28.9

  

5

By different treatment duration

 8

93/101

88.0 (70.7–95.7)

46.2

0.8774

0.2627

5

 12

74/82

89.9 (81.0–94.9)

0.0

  

3

 24

16/18

82.2 (24.9–98.5)

58.2

  

2

  1. aTest of heterogeneity
  2. bTest for subgroup differences